Prediction of Cardiac ATTR Depletion by NI006 ( ALXN2220 ) Using Mechanistic PK / PD Modeling
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Aubin Michalon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurimmune, Schlieren, Switzerland. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Neurimmune AG.
Abstract (Originalsprache)
NI006 (aka ALXN2220) is a therapeutic antibody candidate in phase III clinical development for the depletion of amyloid transthyretin (ATTR) in patients with ATTR cardiomyopathy, an infiltrative cardiomyopathy leading to increased left ventricular wall thickness (LVWT). The mode‐of‐action consists in removal of disease‐causing amyloid accumulations by activating phagocytic immune cells, a mechanism without precedent in cardiology. To select a safe and potentially efficacious dose range and treatment duration for a combined first‐in‐human and proof‐of‐concept clinical phase Ib study, we developed a mechanistic pharmacokinetic and pharmacodynamic (PK/PD) model that can predict NI006 exposure, its effects on cardiac amyloid load and on LWVT, which is a predictor of heart failure in this disease. The PK/PD model predictions supported 0.3 mg/kg monthly dosing as a safe starting dose and identified 10–60 mg/kg monthly as the potentially efficacious dose range with substantial and dose dependent cardiac amyloid burden reduction within 4 months for 60 mg/kg and 10 months for 10 mg/kg. These predictions were in good agreement with the observed primary results of the clinical phase Ib study where amyloid burden was measured by imaging. This novel translational PK/PD model provided important predictions to guide the design of the phase Ib study of NI006, indicating the value of this approach to integrate preclinical results into clinical trial design and increase translational success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neurimmune, Schlieren, Switzerland.
- LYO-X, Basel, Switzerland.
- Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
- Institute for Regenerative Medicine, University of Zurich, Schlieren, Switzerland.
- Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
ORCID-Profile: Aubin Michalon, Lionel Renaud, Matthias Machacek, Cédric Cortijo, Chandrasekhar Udata, Michele F Mercuri, Peter C Kahr, Jan Grimm
Förderung
- Neurimmune AG
Zitieren
APA
Michalon, A., Renaud, L., Machacek, M., Cortijo, C., Udata, C., Mercuri, M. F., Buller, F., Hock, C., Nitsch, R. M., Kahr, P. C., & Grimm, J. (2025). Prediction of Cardiac ATTR Depletion by NI006 ( ALXN2220 ) Using Mechanistic PK / PD Modeling. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3455
Vancouver
Michalon A, Renaud L, Machacek M, Cortijo C, Udata C, Mercuri MF, et al. Prediction of Cardiac ATTR Depletion by NI006 ( ALXN2220 ) Using Mechanistic PK / PD Modeling. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3455
BibTeX
@article{Michalon2025,
author = {Michalon, Aubin and Renaud, Lionel and Machacek, Matthias and Cortijo, Cédric and Udata, Chandrasekhar and Mercuri, Michele F and Buller, Fabian and Hock, Christoph and Nitsch, Roger M and Kahr, Peter C and Grimm, Jan},
title = {Prediction of Cardiac ATTR Depletion by NI006 ( ALXN2220 ) Using Mechanistic PK / PD Modeling},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3455}
}
EUVIMED